SAMHD1 is a key regulator of the lineage-specific response of acute lymphoblastic leukaemias to nelarabine
The nucleoside analogue nelarabine, the prodrug of arabinosylguanine (AraG), is effective against T-cell acute lymphoblastic leukaemia (T-ALL) but not against B-cell ALL (B-ALL). The underlying mechanisms have remained elusive. Here, data from pharmacogenomics studies and a panel of ALL cell lines reveal an inverse correlation between nelarabine sensitivity and the expression of SAMHD1, which can hydrolyse and inactivate triphosphorylated nucleoside analogues. Lower SAMHD1 abundance is detected in T-ALL than in B-ALL in cell lines and patient-derived leukaemic blasts. Mechanistically, T-ALL cells display increased SAMHD1 promoter methylation without increased global DNA methylation. SAMHD1 depletion sensitises B-ALL cells to AraG, while ectopic SAMHD1 expression in SAMHD1-null T-ALL cells induces AraG resistance. SAMHD1 has a larger impact on nelarabine/AraG than on cytarabine in ALL cells. Opposite effects are observed in acute myeloid leukaemia cells, indicating entity-specific differences. In conclusion, SAMHD1 promoter methylation and, in turn, SAMHD1 expression levels determine ALL cell response to nelarabine.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:3 |
|---|---|
| Enthalten in: |
Communications biology - 3(2020), 1 vom: 24. Juni, Seite 324 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rothenburger, Tamara [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 23.06.2021 Date Revised 29.03.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s42003-020-1052-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311596916 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311596916 | ||
| 003 | DE-627 | ||
| 005 | 20240329233039.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s42003-020-1052-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1354.xml |
| 035 | |a (DE-627)NLM311596916 | ||
| 035 | |a (NLM)32581304 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rothenburger, Tamara |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SAMHD1 is a key regulator of the lineage-specific response of acute lymphoblastic leukaemias to nelarabine |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.06.2021 | ||
| 500 | |a Date Revised 29.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The nucleoside analogue nelarabine, the prodrug of arabinosylguanine (AraG), is effective against T-cell acute lymphoblastic leukaemia (T-ALL) but not against B-cell ALL (B-ALL). The underlying mechanisms have remained elusive. Here, data from pharmacogenomics studies and a panel of ALL cell lines reveal an inverse correlation between nelarabine sensitivity and the expression of SAMHD1, which can hydrolyse and inactivate triphosphorylated nucleoside analogues. Lower SAMHD1 abundance is detected in T-ALL than in B-ALL in cell lines and patient-derived leukaemic blasts. Mechanistically, T-ALL cells display increased SAMHD1 promoter methylation without increased global DNA methylation. SAMHD1 depletion sensitises B-ALL cells to AraG, while ectopic SAMHD1 expression in SAMHD1-null T-ALL cells induces AraG resistance. SAMHD1 has a larger impact on nelarabine/AraG than on cytarabine in ALL cells. Opposite effects are observed in acute myeloid leukaemia cells, indicating entity-specific differences. In conclusion, SAMHD1 promoter methylation and, in turn, SAMHD1 expression levels determine ALL cell response to nelarabine | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Arabinonucleosides |2 NLM | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 650 | 7 | |a 9-arabinofuranosylguanine |2 NLM | |
| 650 | 7 | |a 38819-10-2 |2 NLM | |
| 650 | 7 | |a nelarabine |2 NLM | |
| 650 | 7 | |a 60158CV180 |2 NLM | |
| 650 | 7 | |a SAM Domain and HD Domain-Containing Protein 1 |2 NLM | |
| 650 | 7 | |a EC 3.1.5.- |2 NLM | |
| 650 | 7 | |a SAMHD1 protein, human |2 NLM | |
| 650 | 7 | |a EC 3.1.5.- |2 NLM | |
| 700 | 1 | |a McLaughlin, Katie-May |e verfasserin |4 aut | |
| 700 | 1 | |a Herold, Tobias |e verfasserin |4 aut | |
| 700 | 1 | |a Schneider, Constanze |e verfasserin |4 aut | |
| 700 | 1 | |a Oellerich, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Rothweiler, Florian |e verfasserin |4 aut | |
| 700 | 1 | |a Feber, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Fenton, Tim R |e verfasserin |4 aut | |
| 700 | 1 | |a Wass, Mark N |e verfasserin |4 aut | |
| 700 | 1 | |a Keppler, Oliver T |e verfasserin |4 aut | |
| 700 | 1 | |a Michaelis, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Cinatl, Jindrich |c Jr |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Communications biology |d 2018 |g 3(2020), 1 vom: 24. Juni, Seite 324 |w (DE-627)NLM284287245 |x 2399-3642 |7 nnns |
| 773 | 1 | 8 | |g volume:3 |g year:2020 |g number:1 |g day:24 |g month:06 |g pages:324 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s42003-020-1052-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 3 |j 2020 |e 1 |b 24 |c 06 |h 324 | ||